JP2019519221A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519221A5 JP2019519221A5 JP2018560974A JP2018560974A JP2019519221A5 JP 2019519221 A5 JP2019519221 A5 JP 2019519221A5 JP 2018560974 A JP2018560974 A JP 2018560974A JP 2018560974 A JP2018560974 A JP 2018560974A JP 2019519221 A5 JP2019519221 A5 JP 2019519221A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- appendix
- protein
- acid sequence
- viral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021194601A JP7315284B2 (ja) | 2016-05-20 | 2021-11-30 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2023044658A JP2023078338A (ja) | 2016-05-20 | 2023-03-20 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2025028446A JP2025078652A (ja) | 2016-05-20 | 2025-02-25 | 加齢関連疾患及び症状の遺伝子治療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662339182P | 2016-05-20 | 2016-05-20 | |
| US62/339,182 | 2016-05-20 | ||
| US201662421665P | 2016-11-14 | 2016-11-14 | |
| US62/421,665 | 2016-11-14 | ||
| PCT/US2017/033815 WO2017201527A2 (en) | 2016-05-20 | 2017-05-22 | Gene therapy methods for age-related diseases and conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021194601A Division JP7315284B2 (ja) | 2016-05-20 | 2021-11-30 | 加齢関連疾患及び症状の遺伝子治療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519221A JP2019519221A (ja) | 2019-07-11 |
| JP2019519221A5 true JP2019519221A5 (https=) | 2020-08-27 |
| JP7632835B2 JP7632835B2 (ja) | 2025-02-19 |
Family
ID=60326179
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560974A Active JP7632835B2 (ja) | 2016-05-20 | 2017-05-22 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2021194601A Active JP7315284B2 (ja) | 2016-05-20 | 2021-11-30 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2023044658A Pending JP2023078338A (ja) | 2016-05-20 | 2023-03-20 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2025028446A Pending JP2025078652A (ja) | 2016-05-20 | 2025-02-25 | 加齢関連疾患及び症状の遺伝子治療法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021194601A Active JP7315284B2 (ja) | 2016-05-20 | 2021-11-30 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2023044658A Pending JP2023078338A (ja) | 2016-05-20 | 2023-03-20 | 加齢関連疾患及び症状の遺伝子治療法 |
| JP2025028446A Pending JP2025078652A (ja) | 2016-05-20 | 2025-02-25 | 加齢関連疾患及び症状の遺伝子治療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12281154B2 (https=) |
| EP (1) | EP3458585A4 (https=) |
| JP (4) | JP7632835B2 (https=) |
| CN (2) | CN117535350A (https=) |
| AU (2) | AU2017268469C1 (https=) |
| BR (1) | BR112018073861A2 (https=) |
| CA (1) | CA3025020A1 (https=) |
| MX (3) | MX2018014256A (https=) |
| WO (1) | WO2017201527A2 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11208443B2 (en) * | 2017-02-14 | 2021-12-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | NAF-1 derived peptides and uses thereof |
| CN110546257B (zh) * | 2017-03-17 | 2024-03-01 | 阿德夫拉姆生物技术股份有限公司 | 用于增强基因表达的组合物和方法 |
| WO2018215613A1 (en) * | 2017-05-24 | 2018-11-29 | Universitat Autonoma De Barcelona | Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence |
| IL306098A (en) | 2017-05-24 | 2023-11-01 | Univ Barcelona Autonoma | Viral expression vectors containing the coding sequence for FIBROBLAST GROWTH FACTOR 21 (FGF21) |
| BR112020002871A2 (pt) | 2017-08-15 | 2020-07-28 | Kindred Biosciences, Inc. | variantes fc de igg para uso veterinário |
| KR20200077534A (ko) * | 2017-10-20 | 2020-06-30 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 이종 단백질 생성을 위한 인공 분비 펩티드 |
| WO2019113061A1 (en) * | 2017-12-06 | 2019-06-13 | Klogene Therapeutics, Inc. | Compositions and methods for modulating gene expression |
| WO2020047472A1 (en) * | 2018-08-30 | 2020-03-05 | Research Institute At Nationwide Children's Hospital | Gene therapy for the treatment of galactosemia |
| CN113194984A (zh) * | 2018-10-18 | 2021-07-30 | 金德雷德生物科学股份有限公司 | 兽用的与新生儿Fc受体(FcRn)结合改变的Fc变体 |
| US12134772B2 (en) | 2018-11-21 | 2024-11-05 | Advantage Therapeutics, Inc. | Increasing gene expression |
| CN113227126A (zh) * | 2018-11-26 | 2021-08-06 | 巴塞罗那自治大学 | 成纤维细胞生长因子21(fgf21)基因治疗 |
| KR20220030945A (ko) | 2019-05-23 | 2022-03-11 | 크리스티아나 케어 헬스 서비시즈 인코포레이티드 | 암의 치료를 위한 nrf2의 유전자 녹아웃 |
| WO2020237208A1 (en) | 2019-05-23 | 2020-11-26 | Christiana Care Health Services, Inc. | Gene knockout of variant nrf2 for treatment of cancer |
| US20230038502A1 (en) | 2019-06-11 | 2023-02-09 | Shire Human Genetic Therapies, Inc. | Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein |
| US10653731B1 (en) * | 2019-07-15 | 2020-05-19 | Vigene Biosciences Inc. | Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency |
| KR102281858B1 (ko) * | 2019-09-11 | 2021-07-26 | 주식회사 쎌바이오텍 | 유산균 유래 p8 단백질의 발현 컨스트럭트를 포함하는 대장 질환의 치료 또는 예방용 조성물 |
| WO2021050970A1 (en) * | 2019-09-13 | 2021-03-18 | Rutgers, The State University Of New Jersey | Aav-compatible laminin-linker polymerization proteins |
| EP4048800A1 (en) | 2019-10-23 | 2022-08-31 | Shire Human Genetic Therapies, Inc. | Adeno-associated virus vectors based gene therapy for hereditary angioedema |
| CN110894508B (zh) * | 2019-10-31 | 2021-08-06 | 内蒙古大学 | 一种调控白色脂肪棕色化的基因Adra1a的应用 |
| CA3160033A1 (en) * | 2019-12-05 | 2021-06-10 | Paloma Martinez REDONDO | Methods for treating osteoarthritis |
| JP7588466B2 (ja) * | 2020-01-22 | 2024-11-22 | 旭化成メディカル株式会社 | パルボウイルスの生産方法 |
| JP2023524010A (ja) * | 2020-04-28 | 2023-06-08 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 高効率遺伝子送達系 |
| WO2021231730A1 (en) * | 2020-05-13 | 2021-11-18 | Lysogene | Compositions and methods for treating gm1 gangliosidosis and other disorders |
| EP4157317A1 (en) * | 2020-05-26 | 2023-04-05 | Universitat Autònoma De Barcelona | Fibroblast growth factor 21 (fgf21) gene therapy for central nervous system disorders |
| CN114181944B (zh) * | 2020-09-14 | 2023-10-03 | 中国科学院动物研究所 | 突变基因及构建短肢性侏儒症小型猪模型的方法和用途 |
| WO2022115739A2 (en) * | 2020-11-30 | 2022-06-02 | Cellular Longevity, Inc. | Lnp and liposome compositions for longevity in mammals and methods of using the same |
| US20220186252A1 (en) | 2020-12-16 | 2022-06-16 | Takeda Pharmaceutical Company Limited | Adeno associated viral vector delivery of antibodies for the treatment of disease mediated by dysregulated plasma kallikrein |
| KR102590276B1 (ko) * | 2021-01-04 | 2023-10-16 | 부산대학교 산학협력단 | 조직 특이적 발현을 위한 융합 프로모터 및 이의 용도 |
| CN113444730A (zh) * | 2021-03-17 | 2021-09-28 | 昆明市延安医院 | 一种原发性肝细胞klotho基因转导干细胞筛选构建方法 |
| CN113088531B (zh) * | 2021-03-25 | 2023-10-17 | 四川省药品检验研究院(四川省医疗器械检测中心) | 牛源性成分定量分析标准质粒、制备及检测方法及应用 |
| WO2022221291A2 (en) * | 2021-04-12 | 2022-10-20 | University Of Florida Research Foundation Incorporated | Compositions and methods for treating obesity |
| JP2022169389A (ja) * | 2021-04-27 | 2022-11-09 | 国立大学法人北海道大学 | イヌＴＧＦ－β受容体ＩＩ |
| US12564646B2 (en) * | 2021-06-16 | 2026-03-03 | BioViva USA, Inc. | Treatment of age-related cognitive decline using genetically modified viral vectors |
| US20230018934A1 (en) * | 2021-07-16 | 2023-01-19 | Genflow Biosciences Srl | Method of in vivo administration of the coding sequence of the sirt6 gene via adeno-associated virus |
| EP4408482A4 (en) * | 2021-09-29 | 2025-11-12 | Sirt6 Ltd | METHOD OF TREATING A DISEASE |
| CN114921480A (zh) * | 2022-06-09 | 2022-08-19 | 国科宁波生命与健康产业研究院 | 一种骨细胞Terc基因敲除小鼠模型的构建方法 |
| US20260102513A1 (en) * | 2022-09-21 | 2026-04-16 | Rejuvenate Bio | Gene therapy methods for arrhythmogenic cardiomyopathy |
| WO2024064785A2 (en) * | 2022-09-21 | 2024-03-28 | Rejuvenate Bio | Gene therapy methods for familial partial lipodystrophy |
| WO2024064784A2 (en) * | 2022-09-21 | 2024-03-28 | Rejuvenate Bio | Gene therapy methods for treating mitral valve disease |
| CN116790610B (zh) * | 2023-05-18 | 2024-09-20 | 四川大学 | 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物 |
| EP4566618A1 (en) * | 2023-12-06 | 2025-06-11 | ADvantage Therapeutics, Inc. | Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight |
| WO2025109173A1 (en) | 2023-11-22 | 2025-05-30 | Advantage Therapeutics, Inc. | Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight |
| WO2026002276A1 (zh) * | 2024-06-28 | 2026-01-02 | 艾码生物科技(南京)有限公司 | 靶向tgfb的rna干扰方法、核酸及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824655A (en) * | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
| JP2001515360A (ja) | 1997-04-18 | 2001-09-18 | バイオジェン，インコーポレイテッド | ▲ＩＩ▼型ＴＧＦ−βレセプター／免疫グロブリン定常領域融合タンパク質 |
| US7622300B2 (en) * | 1998-06-03 | 2009-11-24 | Kappes John C | Trans-lentiviral vector particles and transduction of eukaryotic cells therewith |
| US7419829B2 (en) * | 2000-10-06 | 2008-09-02 | Oxford Biomedica (Uk) Limited | Vector system |
| WO2003059396A1 (en) | 2002-01-11 | 2003-07-24 | Sergei Zolotukhin | Adiponectin gene therapy |
| US8158589B2 (en) * | 2003-08-22 | 2012-04-17 | Proyecto Biomedicine Cima, S.L. | Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1) |
| WO2006052568A2 (en) * | 2004-11-10 | 2006-05-18 | Eli Lilly And Company | Tgf-beta inhibitors |
| FR2879204B1 (fr) * | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
| ATE505489T1 (de) * | 2005-04-22 | 2011-04-15 | Lilly Co Eli | Tgf-beta-1-spezifische antikörper |
| DE102005061840A1 (de) * | 2005-12-23 | 2007-06-28 | Merck Patent Gmbh | Triazolderivate |
| US20070292922A1 (en) | 2006-03-31 | 2007-12-20 | Cell Genesys, Inc. | Regulated expression of recombinant proteins from adeno-associated viral vectors |
| JP5421109B2 (ja) | 2006-09-13 | 2014-02-19 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | 低カルボキシル化／非カルボキシル化オステオカルシンはベータ細胞増殖、インスリン分泌、インスリン感受性、耐糖能を増加させ、体脂肪量を減少させる |
| EP2171062A1 (en) * | 2007-06-15 | 2010-04-07 | Genzyme Corporation | Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor |
| US8236557B2 (en) * | 2008-05-28 | 2012-08-07 | University Of Missouri-Columbia | Hybrid-AAV vectors to deliver large gene expression cassette |
| JO3096B1 (ar) * | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| CA3083324A1 (en) * | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| AR083445A1 (es) * | 2010-10-14 | 2013-02-27 | Univ Mie | siARN CONTRA LA FIBROSIS |
| EP2455104B1 (en) * | 2010-11-19 | 2013-07-17 | Universitätsklinikum Freiburg | Bio-functionalized stimulus-responsive dissolvable PEG-hydrogels |
| EP2548570A1 (en) * | 2011-07-19 | 2013-01-23 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
| MX2014002260A (es) | 2011-08-31 | 2014-08-18 | Amgen Inc | Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1. |
| UY34346A (es) * | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de fusión para tratar trastornos metabólicos |
| TWI614031B (zh) | 2011-11-03 | 2018-02-11 | 國立陽明大學 | 防止皮膚老化相關症狀的醫藥組合物及其使用方法 |
| US9422561B2 (en) | 2012-01-24 | 2016-08-23 | Bar-Ilan University | Treatment of disease by modulation of SIRT6 |
| CN103665166A (zh) * | 2012-09-03 | 2014-03-26 | 福又达生物科技股份有限公司 | 犬融合干扰素 |
| WO2014152993A1 (en) * | 2013-03-14 | 2014-09-25 | The Board Of Regents Of The University Of Oklahoma | Use of klotho nucleic acids or proteins for treatment of diabetes and diabetes-related conditions |
| US10227394B2 (en) * | 2014-04-08 | 2019-03-12 | University Of Southern California | Polypeptide compositions with type VII collagen fibronectin type III-like repeats and treatment methods for wound closure and healing |
| KR20150135148A (ko) * | 2014-05-23 | 2015-12-02 | 주식회사 제넥신 | Pd-l1 융합 단백질 및 이의 용도 |
| SMT202100388T1 (it) * | 2014-10-24 | 2021-09-14 | Bristol Myers Squibb Co | Polipeptidi fgf-21 modificati e loro usi |
| KR20160088656A (ko) * | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| US10882894B2 (en) * | 2015-08-11 | 2021-01-05 | Anie Philip | Peptidic TGF-beta antagonists |
-
2017
- 2017-05-22 JP JP2018560974A patent/JP7632835B2/ja active Active
- 2017-05-22 US US16/302,865 patent/US12281154B2/en active Active
- 2017-05-22 WO PCT/US2017/033815 patent/WO2017201527A2/en not_active Ceased
- 2017-05-22 CN CN202311189446.9A patent/CN117535350A/zh active Pending
- 2017-05-22 EP EP17800329.9A patent/EP3458585A4/en active Pending
- 2017-05-22 CA CA3025020A patent/CA3025020A1/en active Pending
- 2017-05-22 MX MX2018014256A patent/MX2018014256A/es unknown
- 2017-05-22 CN CN201780058862.1A patent/CN109844124B/zh active Active
- 2017-05-22 BR BR112018073861-1A patent/BR112018073861A2/pt active Search and Examination
- 2017-05-22 AU AU2017268469A patent/AU2017268469C1/en active Active
-
2018
- 2018-11-20 MX MX2022000085A patent/MX2022000085A/es unknown
- 2018-11-20 MX MX2025014039A patent/MX2025014039A/es unknown
-
2021
- 2021-11-30 JP JP2021194601A patent/JP7315284B2/ja active Active
-
2023
- 2023-03-20 JP JP2023044658A patent/JP2023078338A/ja active Pending
-
2024
- 2024-09-23 AU AU2024219991A patent/AU2024219991A1/en active Pending
- 2024-11-11 US US18/942,898 patent/US20250122267A1/en active Pending
-
2025
- 2025-02-25 JP JP2025028446A patent/JP2025078652A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019519221A5 (https=) | ||
| Skopenkova et al. | Muscle-specific promoters for gene therapy | |
| US7351577B2 (en) | Adeno-associated vector compositions for expression of Factor VIII | |
| JP2022033855A (ja) | 加齢関連疾患及び症状の遺伝子治療法 | |
| JP2022033855A5 (https=) | ||
| IL299325B2 (en) | Acid-alpha glucosidase variants and uses thereof | |
| JP7659550B2 (ja) | アデノ随伴ウイルスベクターに基づく遺伝性血管浮腫のための遺伝子治療 | |
| JP2002527493A (ja) | 標的細胞による第ｖｉｉｉ因子の発現のためのアデノ随伴ベクター | |
| CN113316639A (zh) | 用于治疗庞贝氏病的治疗性腺相关病毒 | |
| US6967018B2 (en) | Adiponectin gene therapy | |
| JP2012521750A (ja) | 肝硬変及び肝線維症の治療のための方法及び組成物 | |
| JP2022512689A (ja) | ジスルフィド結合により安定したポリペプチド組成物及びその使用方法 | |
| CN121575014A (zh) | 成纤维细胞生长因子23相关的低磷酸盐血症的基因治疗 | |
| JP2022527597A (ja) | 筋肉発現のためのハイブリッドプロモーター | |
| JP2021532810A (ja) | 糖原病ｉｉｉの処置のためのミニｇｄｅ | |
| JP2023076698A (ja) | ２１－ヒドロキシラーゼ欠損症のためのアデノ随伴ウイルス遺伝子療法 | |
| JP2025535114A (ja) | 中枢神経系における遺伝子発現のための核酸調節エレメント及び使用方法 | |
| JP2021520811A5 (https=) | ||
| JP2018526994A (ja) | ペット治療用ａａｖ−ｅｐｏ | |
| TWI883088B (zh) | 用於治療韓特氏病之腺相關病毒載體 | |
| US20260092290A1 (en) | Recombinant viral vector, recombinant adeno-associated virus comprising the same, and uses thereof in treating sialidosis | |
| JP2002534077A (ja) | トランスジェニック動物における分泌型ヒトアルファ−フェト蛋白質の発現 | |
| KR20230112672A (ko) | 신경변성 질환을 위한 유전자 요법 | |
| US20250327080A1 (en) | Rnas targeting activin a subunits | |
| CN120665952A (zh) | 一种修复肌萎缩侧索硬化致病突变基因的编辑系统 |